



HUTCHISON CHINA MEDITECH LTD

For Immediate Release

26 February 2007

**Hutchison China MediTech Limited
(AIM: HCM)**

Notice of Preliminary Results

Hutchison China MediTech Limited ("Chi-Med") will announce its preliminary results for the year ended 31 December 2006 on Wednesday, 21 March 2007.

Ends

Enquiries

Chi-Med

Christian Hogg, CEO

Telephone: +852 2121 8200

Citigate Dewe Rogerson

Anthony Carlisle

Yvonne Alexander

Telephone: +44 (0) 20 7638 9571

+44 (0) 7973 611 888

+44 (0) 7866 610 682

About Chi-Med

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. Chi-Med is focused on researching, developing, manufacturing, and selling pharmaceuticals, health supplements and other consumer health and personal care products derived from Traditional Chinese Medicine ("TCM") and botanical ingredients. Its overall aim is to draw on the untapped wealth of knowledge and history of usage in the TCM industry to develop products for the global market. Chi-Med has three complementary businesses: drug R&D, China healthcare and consumer products.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international corporation listed on the Main Board of The Stock Exchange of Hong Kong Limited.